venerdƬ, Novembre 22, 2024

Gli isocianati, intermedi industriali molto utili ma pericolosi: esposizione professionale, effetti e regolamentazione

Cosa sono gli isocianati Gli isocianati sono una famiglia di...

Infiammazione cronica silente: la causa sottostante all’anemia cronica dell’anziano

L'invecchiamento ĆØ un processo inevitabile che ĆØ influenzato dalla...

Parkinson’s disease: blocking the channel would spare neurons’ life

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease, and causes motor symptoms such as tremor, bradykinesia, rigidity and postural instability and autonomic dysfunction due to a preferential loss of dopaminergic neurons in the substantia nigra. For 90% of Parkinson’s disease patients, symptoms are idiopathic and it is difficult to understand the relationship between various factors, including those associated with the environment (toxins, heavy metals), and the disease mechanism. However, approximately 10% of patients show the familial incidence of Parkinson’s disease. Therefore understanding the disease mechanism for familial Parkinson’s disease may also link with the understanding of Parkinson’s disease including idiopathic Parkinson’s disease as well as drug development. Standard therapy of the condition is based onto Levo-DOPA administration as monotherapy (almost not employed anymore), but more frequently associated to other dopaminergic agonists. Nevertheless, none of existing drugs is able to prevent the death of neuron in substantia nigra (the specific brain region implicated)

A joint research group centered around Professor Hideyuki Okano and Associate Professor Jun Kohyama, Department of Physiology of the Keio University School of Medicine, together with a research group of Eisai Co., Ltd. has identified a compound that has the potential to be a treatment for Parkinson’s disease by using dopaminergic neurons differentiated from induced pluripotent stem cellsĀ (iPS)Ā from patients with familial Parkinson’s disease. Aiming to develop treatments for Parkinson’s disease, this research group utilized neural progenitor cells induced from iPS cells derived from patients with familial Parkinson’s disease and established a differentiation protocol for the stable supply of a large number of dopaminergic neurons. Furthermore, the research group screened an existing drug library as an indicator of susceptibility to stress observed in dopaminergic neurons derived from Parkinson’s disease patients, and identified compounds that inhibit calcium channels. Further detailed analysis conducted by the research group revealed higher expression of T-type calcium channels in dopaminergic neurons derived from PARK2 patients.

It was also found that apoptosis of dopaminergic neurons derived from Parkinson’s disease patients could be reduced by inhibiting calcium influx via T-type calcium channels. From these results, it is suggested that combining disease specific iPS cells and existing drug library has potential for both the development of treatments and clarification of disease pathology. Through the use of iPS cell technologies developed by Professor Shinya Yamanaka of Kyoto University in 2006, research has made great advances even in diseases that were difficult to be investigated by conventional methods. In 2012, the Keio University School of Medicine became the first research facility in Japan to create iPS cells from patients with familial Parkinson’s disease, and was successful in replicating the disease mechanism. Currently research into neurological diseases has become very active throughout the world, and the understanding of diseases and development of new treatments is highly anticipated. In April 2013, the Keio University School of Medicine and Eisai initiated the “Innovative Drug Discovery Project for Refractory Neurological Diseases Using iPS Cell Technologiesā€.Through this research, dopaminergic neurons which are thought to be damaged in Parkinson’s disease patients are created efficiently and easily using iPS cells derived from Parkinson’s disease patients, and an experimental system for conducting screening for drug discovery was established.

In this research, Keio University School of Medicine’s library of over 1,000 existing drugs was screened to find compounds preventing increased susceptibility to stress in dopaminergic neurons derived from Parkinson’s disease patients. In this research, neural progenitor cells induced from iPS cells established from two familial Parkinson’s disease (PARK2) patients were used to efficiently generate dopaminergic neurons. In patient-derived neurons, reduced neurite length as well as elevated oxidative stress and apoptosis were observed compared to neurons derived from healthy controls. Furthermore, it was revealed that these disease-relevant phenotypes were also observed in dopaminergic neurons derived from isogenic PARK2 null iPS cells obtained by genome editing. In addition, since patient-derived dopaminergic neurons showed high susceptibility to rotenone, a mitochondrial respiratory chain complex I inhibitor, an existing drug library was screened with vulnerability to this drug-induced stress as the target. From phenotypic screening with an existing drug library, several compounds that suppressed stress-induced apoptosis were identified.

Furthermore, it was found that T-type calcium channel antagonists effectively reduced stress-induced apoptosis. Importantly, these compounds demonstrated similar reduction in stress-induced apoptosis in dopaminergic neurons derived from other type of familial Parkinson’s disease (PARK6) patients who possess a genetic abnormality which is different to PARK2. Further detailed analysis conducted by the research group revealed higher expression of T-type calcium channels in dopaminergic neurons derived from PARK2 patients. It was also found that apoptosis of dopaminergic neurons derived from Parkinson’s disease patients could be reduced by inhibiting calcium influx via T-type calcium channels. From these results, using iPS cells derived from patients enabled the establishment of in vitro disease models that reflect human biology, and by further combining with existing drug library, suggested efficacy for drug screening. By promoting the understanding of disease pathology through this method, it is hoped that this will lead to application in the development of a fundamental treatment for Parkinson’s disease.

  • edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochiemistry.

Scientific references

Man JHK et al.Ā J Control Release. 2018 Sep 28; 286:114-24.Ā 

Barker RA et al.Ā Cell Stem Cell. 2017 Nov 2; 21(5):569-573.Ā 

Morizane A et al.Ā Nature Commun. 2017 Aug 30; 8(1):385.

Latest

Infiammazione cronica silente: la causa sottostante all’anemia cronica dell’anziano

L'invecchiamento ĆØ un processo inevitabile che ĆØ influenzato dalla...

I grani antichi: un bene prezioso da rivalutare per i loro benefici sulla salute

I cereali integrali sono una componente fondamentale di una...

Newsletter

Don't miss

Infiammazione cronica silente: la causa sottostante all’anemia cronica dell’anziano

L'invecchiamento ĆØ un processo inevitabile che ĆØ influenzato dalla...

I grani antichi: un bene prezioso da rivalutare per i loro benefici sulla salute

I cereali integrali sono una componente fondamentale di una...

Mappatura 3D dei tumori: l’aiuto dell’Intelligenza Artificiale nella biologia del cancro

3D tumor Mmping in cancer biology 3D tumor mapping in...
Dott. Gianfrancesco Cormaci
Dott. Gianfrancesco Cormaci
Laurea in Medicina e Chirurgia nel 1998; specialista in Biochimica Clinica dal 2002; dottorato in Neurobiologia nel 2006; Ex-ricercatore, ha trascorso 5 anni negli USA (2004-2008) alle dipendenze dell' NIH/NIDA e poi della Johns Hopkins University. Guardia medica presso la casa di Cura Sant'Agata a Catania. Medico penitenziario presso CC.SR. Cavadonna (SR) Si occupa di Medicina Preventiva personalizzata e intolleranze alimentari. Detentore di un brevetto per la fabbricazione di sfarinati gluten-free a partire da regolare farina di grano. Responsabile della sezione R&D della CoFood s.r.l. per la ricerca e sviluppo di nuovi prodotti alimentari, inclusi quelli a fini medici speciali.

Medicina di genere (1.1): le differenze di pressione fra uomo e donna svelate da un antiossidante

Un antiossidante, la tetrabiopterina, sembra aiutare a livellare il campo di gioco tra i maschi e le femmine in profonditĆ  allā€™interno dei reni ā€“...

Ataxia-teleangectasia: il gene malato rivela una nuova funzione

Una ragione per cui dovremmo mangiare una varietĆ  di frutta e verdura colorata ĆØ perchĆ© contengono composti nutrienti chiamati antiossidanti. Queste molecole contrastano il...

Microbiota e mycobiota: i due inquilini che risentono in modo opposto agli antibiotici

Il microbiota intestinale include batteri, funghi, specie archea, virus e talvolta protozoi ed ĆØ un fattore importante che contribuisce alla salute umana. La maggior...

Questo si chiuderĆ  in 20 secondi